2. Academic Validation
  3. Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis

Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis

  • J Oncol. 2022 May 31:2022:9390611. doi: 10.1155/2022/9390611.
Haibo Zhan 1 2 3,  Jun Xiao 1 2,  Po Wang 1 2,  Fengbo Mo 1 2,  Kaihuang Li 1 2,  Fengfen Guo 1 2,  Xiaolong Yu 1 2,  Xuqiang Liu 1 2,  Bin Zhang 1 2,  Min Dai 1 2,  Hucheng Liu 1 2
Affiliations

Affiliations

  • 1 Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi, China.
  • 2 Artificial Joints Engineering and Technology Research Center of Jiangxi Province, Nanchang, 330006 Jiangxi, China.
  • 3 Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi, China.
PMID: 35693981 DOI: 10.1155/2022/9390611
Abstract

Cancer-derived exosomes participate in carcinogenesis and progression of cancers, including metastasis and drug-resistance. Of note, CTCF has been suggested to induce drug resistance in various cancers. Herein, we aim to investigate the role of cisplatin- (CDDP-) resistant osteosarcoma- (OS-) derived exosomal CTCF in OS cell resistance to CDDP and its mechanistic basis. Differentially expressed transcription factors, long noncoding RNAs (lncRNAs), miRNAs, and genes in OS were retrieved using bioinformatics approaches. Exosomes were extracted from CDDP-resistant OS cells and then cocultured with parental OS cells, followed by lentiviral transduction to manipulate the expression of CTCF, IGF2-AS, miR-579-3p, and MSH6. We assessed the in vitro and in vivo effects on malignant phenotypes, Autophagy, CDDP sensitivity, and tumor formation of OS cells. It was established that CTCF and IGF2-AS were highly expressed in CDDP-resistant OS cells, and the CDDP-resistant OS cell-derived exosomal CTCF enhanced IGF2-AS transcription. CDDP-resistant OS-derived exosomes transmitted CTCF to OS cells and increased CDDP resistance in OS cells by activating an autophagy-dependent pathway. Mechanistically, CTCF activated IGF2-AS transcription and IGF2-AS competitively bound to miR-579-3p to upregulate MSH6 expression. Additionally, the promoting function of exosomal CTCF-mediated IGF2-AS/miR-579-3p/MSH6 in OS cell resistance to CDDP was confirmed in vivo. Taken together, CDDP-resistant OS-derived exosomal CTCF enhanced resistance of OS cells to CDDP via activating the autophagy-dependent pathway, providing a potential therapeutic consideration for OS treatment.

Figures
Products